Drugs / Apraglutide
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06002555 | May → Sep 2023 | — | VectivBio AG | Completed | No outcome recorded |
| Phase 1 | NCT05995704 | Mar → Jul 2023 | — | VectivBio AG | Completed | No outcome recorded |
| Phase 1 | NCT05706623 | Jan → Apr 2023 | — | VectivBio AG | Completed | No outcome recorded |
| Phase 1 | NCT04699032 | Dec 2020 → Jul 2021 | chronic kidney disease | VectivBio AG | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05415410 | May 2022 → Dec 2024 | acute graft versus host disease | VectivBio AG | Terminated | No outcome recorded |
| Phase 2 | NCT04964986 | Jun 2021 → Jun 2023 | short bowel syndrome | VectivBio AG | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05018286 | Jul 2021 → Oct 2027 expected | short bowel syndrome | VectivBio AG | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04627025 | Jan 2021 → Jan 2024 | short bowel syndrome | VectivBio AG | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Apraglutide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04964986 ↗ |
| Action | Activate | “acts as a full agonist at the GLP-2 receptor” NCT04627025 ↗ |
| Modality | Peptide | “Peptide analogue of GLP-2” NCT04627025 ↗ |
| Route | Subcutaneous | “weekly SC injections of apraglutide” NCT04627025 ↗ |